You are here: Industry Insights > Merck

News List

Merck’s Isentress receives CHMP positive opinion to treat HIV-1 infection pharmaceutical-technology
May 27, 2017
Merck’s Isentress (raltegravir) 600mg film-coated tablets have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for the treatment of HIV-1 infection in adults and paediatric
Merck, Stelis Open First Joint Process Scale-Up Lab in Bengaluru contractpharma
May 26, 2017
Combines Stelis' bioprocess development capabilities with Merck's bioprocessing equipment
FDA approves Merck’s bladder cancer drug europeanpharmaceuticalreview
May 25, 2017
The US Food and Drug Administration (FDA) has approved two new indications for Merck’s (known as MSD outside the US and Canada) Keytruda (pembrolizumab).
Merck Develops Alternative CRISPR Genome Editing Method americanpharmaceuticalreview
May 18, 2017
Merck has developed a new genome editing tool that makes CRISPR more efficient, flexible and specific, giving researchers more experimental options and faster results that can accelerate drug development and access to new therapies.
Merck Launches Industry's First Off-the-Shelf Cell Culture Media for Perfusion Processes en-cphi.cn
May 16, 2017
Increases manufacturing flexibility; Exceptional performance and consistency required for high-density perfusion cell culture processes
How Merck & Co. (MRK) Could Have Lucked Into a $10 Billion Drug BioSpace.com
May 15, 2017
The stars have lined up for Merck (MRK) as analysts suggest its checkpoint inhibitor Keytruda could yield $6 billion in revenue in 2018 and could grow to $10 billion by 2022.
Merck expands M Lab Collaboration Center in Bengaluru financialexpress
May 15, 2017
The facility will provide biopharmaceutical manufacturers with a shared, exploratory environment where they can collaborate with Merck scientists and engineers to solve their toughest challenges
FDA grants approval to Merck & Co.'s Keytruda as first-line combination therapy in NSCLC firstwordpharma
May 11, 2017
Merck & Co. announced Wednesday that the FDA awarded accelerated approval to Keytruda (pembrolizumab), in combination with Eli Lilly's Alimta (pemetrexed) and carboplatin.
Merck acquires Grzybowski Scientific Inventions to expand chemical synthesis offering worldpharmanews
May 11, 2017
Merck, a leading science and technology company, today announced the acquisition of Grzybowski Scientific Inventions (GSI), a company that developed the revolutionary computer-aided retro-synthesis tool, Chematica.
Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma pharmaceutical-technology
May 09, 2017
Merck has received approval from the European Commission (EC) for Keytruda (pembrolizumab) to treat adult patients affected with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page